Preferred Label : Oncolytic Vaccinia Virus Expressing Anti-CTLA-4 Antibody and GM-CSF BT-001;
NCIt synonyms : Oncolytic VV Expressing Anti-CTLA4 Antibody and GM-CSF BT-001;
NCIt definition : An oncolytic vaccinia virus (VV; VACV) genetically engineered to express 4-E03, an
immunoglobulin G1 (IgG1) antibody directed against the human inhibitory T-cell-expressed
receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4) and the immunostimulatory
cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential
oncolytic, immunostimulating and antineoplastic activities. Upon intra-tumoral administration,
the oncolytic VV expressing anti-CTLA-4 antibody and GM-CSF BT-001 specifically infects
and replicates in tumor cells causing viral-mediated tumor cell lysis. The released
virus particles, in turn, infect and replicate in neighboring tumor cells. Tumor antigens
released from the lysed tumor cells also activate the immune system to induce a tumor-specific
systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby
non-infected tumor cells. In addition, oncolytic virus BT-001 promotes the secretion
of anti-CTLA-4 antibody 4-E03 and GM-CSF by the tumor cells. GM-CSF attracts dendritic
cells (DCs) and may further stimulate a CTL-mediated immune response against tumor
cells. Anti-CTLA-4 antibody 4-E03 targets and binds to CTLA-4 expressed on T-cells,
and inhibits the CTLA-4-mediated downregulation of T-cell activation. This enhances
the CTL-mediated immune response against tumor cells. CTLA-4, an inhibitory receptor
and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation
of the immune system.;
Molecule name : TG-6030; TG 6030; BT-001; BT 001;
NCI Metathesaurus CUI : CL1662165;
Origin ID : C179623;
UMLS CUI : C5557575;
Semantic type(s)
- concept_is_in_subset
